Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2026-05-13 Proxy Solicitation & In…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Notice of Annual General Meeting on 27 May 2026 - Attachment: 20260513_Arctic_Bioscience_AS_Notice_AGM_2026.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is the formal notice to shareholders of Arctic Bioscience AS of its annual general meeting, including the agenda, proposals (e.g. approval of accounts, election of board members, authorization for capital increase), voting instructions, proxy and advance vote procedures. It is sent to shareholders to provide information and solicit votes. This matches the definition of Proxy Solicitation & Information Statement (PSI), not the actual AGM presentations or the post-meeting voting results.
2026-05-13 Norwegian Bokmål
Arctic Bioscience - Innkalling til ordinær generalforsamling 27. mai 2026 - Attachment: 20260513_Arctic_Bioscience_AS_Notice_AGM_2026.pdf
Proxy Solicitation & Information Statement Classification · 96% confidence The document is the formal notice (‘Innkalling’) convening the company’s Annual General Meeting, setting out the agenda items (annual accounts, board elections, capital authorization, etc.) and providing detailed proxy and advance voting instructions. It is sent to shareholders to solicit proxies and inform them ahead of the meeting, rather than presenting the actual financial report or results. This matches our definition of Proxy Solicitation & Information Statement (PSI).
2026-05-13 Norwegian Bokmål
Arctic Bioscience - Notice of Annual General Meeting on 27 May 2026
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a notice of the company’s Annual General Meeting, providing meeting date, agenda items, proxy voting instructions, and proposed board elections. It is soliciting shareholder votes and proxy authorizations for the AGM, fitting the definition of Proxy Solicitation & Information Statement rather than a post-meeting report or management announcement.
2026-05-13 English
Arctic Bioscience - Innkalling til ordinær generalforsamling 27. mai 2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an official notice convening the company’s ordinary general meeting (“innkalling til ordinær generalforsamling”), providing voting instructions, proxy forms, agenda items (board elections), and logistical details for shareholders. This aligns with materials sent to shareholders to inform and solicit votes for the AGM rather than the AGM presentation itself or a full annual report. Therefore, it fits “Proxy Solicitation & Information Statement” (PSI).
2026-05-13 Norwegian Bokmål
Arctic Bioscience presenterer HeROPA-data på EADV i Athen - Attachment: Poster_EADV_spring_2026.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed clinical trial report presenting efficacy and safety results from the HeROPA phase 2b trial of the drug HRO350 for mild-to-moderate psoriasis. It includes study design, patient population, treatment arms, statistical analyses, and detailed outcome data over a 52-week period. The content is scientific and medical in nature, focusing on treatment response, biomarker stratification, and adverse events. There is no indication that this is a financial or corporate filing, nor does it relate to any of the specified financial or corporate report categories such as Annual Report, Earnings Release, or Regulatory Filings. The document is a clinical study report or scientific research report, which does not fit into any of the provided financial filing categories. Therefore, the best fit under the given taxonomy is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit into other specific categories.
2026-05-08 Norwegian
Arctic Bioscience presents HeROPA data at EADV in Athens - Attachment: Poster_EADV_spring_2026.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed clinical trial report presenting the results of the HeROPA phase 2b trial evaluating the treatment HRO350 for mild-to-moderate psoriasis. It includes comprehensive efficacy results, safety data, statistical analyses, and methodological details. The content is scientific and medical in nature, focusing on treatment response, biomarkers, and patient stratification. There is no indication that this is a financial or corporate filing, nor does it fit any of the financial or corporate report categories such as Annual Report, Earnings Release, or Regulatory Filings. The document is a clinical study report, which does not align with any of the provided financial filing categories. Therefore, the best fit under the given taxonomy is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2026-05-08 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.